Utah Medical Products (UTMD) Invested Capital (2010 - 2026)

Utah Medical Products has reported Invested Capital for 17 years, with the latest figure at $120.4 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 2.84% year-over-year to $120.4 million; the trailing twelve-month figure through Mar 2026 stood at $120.4 million (up 2.84% YoY), and the FY2025 full-year result was $119.3 million, up 1.57% from the prior year.
• Invested Capital for Q1 2026 stood at $120.4 million, up from $119.3 million in the prior quarter.
• The five-year high for Invested Capital was $128.3 million in Q4 2023, with the low at $107.5 million in Q2 2022.
• Average Invested Capital over 5 years is $118.6 million, with a median of $118.3 million recorded in 2025.
• Year-over-year, Invested Capital increased 14.34% in 2023 and decreased 8.48% in 2024.
• Tracing UTMD's Invested Capital over 5 years: stood at $114.3 million in 2022, then grew by 12.3% to $128.3 million in 2023, then declined by 8.48% to $117.4 million in 2024, then climbed by 1.57% to $119.3 million in 2025, then increased by 0.93% to $120.4 million in 2026.
• The last three Invested Capital figures came in at $120.4 million (Q1 2026), $119.3 million (Q4 2025), and $118.3 million (Q3 2025), per Business Quant data.

Peer Comparison